![](https://webarchive.library.unt.edu/eot2008/20090509163603im_/http://www.cancer.gov/images/spacer.gif) |
|
![](https://webarchive.library.unt.edu/eot2008/20090509163603im_/http://www.cancer.gov/images/spacer.gif)
basiliximab A recombinant, chimeric, human-murine monoclonal antibody directed against the alpha subunit of the interleukin-2 receptor (IL-2R alpha) with immunosuppressant activity. Basiliximab selectively binds to and blocks IL-2R alpha, expressed on the surface of activated T-lymphocytes, thereby preventing interleukin-2 binding and inhibiting the interleukin-2-mediated activation of lymphocytes. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
![](https://webarchive.library.unt.edu/eot2008/20090509163603im_/http://www.cancer.gov/images/spacer.gif)
US brand name: | ![](https://webarchive.library.unt.edu/eot2008/20090509163603im_/http://www.cancer.gov/images/spacer.gif) | Simulect | | ![](https://webarchive.library.unt.edu/eot2008/20090509163603im_/http://www.cancer.gov/images/spacer.gif) | Code name: | ![](https://webarchive.library.unt.edu/eot2008/20090509163603im_/http://www.cancer.gov/images/spacer.gif) | SDZ-CHI-621 | | ![](https://webarchive.library.unt.edu/eot2008/20090509163603im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20090509163603im_/http://www.cancer.gov/images/spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20090509163603im_/http://www.cancer.gov/images/gray_spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20090509163603im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/eot2008/20090509163603im_/http://www.cancer.gov/images/spacer.gif) |